Allergic Rhinitis. Allergic rhinitis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Receiving 15mg of Maa-al-shaeer powder in 250cc water, twice a day for 2 weeks. Intervention 2: Control Group: Receiving Fexofenadine tablets 60mg twice a day for 2
Treatment - Drugs
Intervention group: Receiving 15mg of Maa-al-shaeer powder in 250cc water, twice a day for 2 weeks
Control Group: Receiving Fexofenadine tablets 60mg twice a day for 2 weeks
Sponsors
Vice chancellor for research, Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
7 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients 7 years to 65 years old that according to the ARIA guideline and diagnosis of a pulmonologist have allergic rhinitis a Exclusion criteria: Diffused Nasal Polyps; Pregnancy; history of allergy to Fexofenadine or barley; Celiac disease; systemic inflammatory diseases; using antihistamines during the last week before the beginning of the study; using Corticosteroids during the last 2 weeks before the beginning of the study; Using other antihistamine drugs during the study; using corticosteroid drugs during the study; Lack of consent from the patient to stay in the study for any reason; drug intolerance or allergic reactions
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: JTFPP questionnaire and based on VAS.;IFN-gamma. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;IL-4. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;IL-17. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;TGF-beta. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;Ig-E levels. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample / IU/ml.;Blood Eosinophil level. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample / IU/ml.;Nasal smear eosinophil count. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: eosinophil count in nasal smear. | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom recurrence rate. Timepoint: Baseline and one week after the end of intervention. Method of measurement: RCAT questionnaire.;Levels of AST, ALT, BUN, Cr in the group taking the Ma-al-Shaeer to evaluate its effect on hepatic and renal function. Timepoint: Baseline and two weeks after intervention. Method of measurement: blood samples. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Alireza Derakhshan
School of Traditional Medicine, Shahid Beheshti University of Medical Sciences
Outcome results
None listed